Announcements Trials
Browse Landscape

Status

Completed 4Withdrawn 1

Sponsor Class

INDUSTRY 3OTHER 2

Study Type

Interventional 62Observational 5Expanded_access 1

Sponsor

Cancer Type

Other hematologic neoplasm 10Myeloid 5Lymphoid 2

Conditions

Leukemia, Myelogenous, Chronic, BCR-ABL Positive 5Leukemia, Myeloid, Chronic-Phase 1

Interventions

Blood Specimen Collection 15Imatinib Mesylate 10Flow Cytometry 10nilotinib 8Surveys and Questionnaires 8Polymerase Chain Reaction 8ponatinib 6Cytogenetic Analysis 6ruxolitinib 5bosutinib 5Psychiatric Rehabilitation 5Dasatinib 5Therapeutics 4Interviews as Topic 4Biopsy 4asciminib 3Observation 3Microarray Analysis 3In Situ Hybridization, Fluorescence 3Immunoenzyme Techniques 3Amplified Fragment Length Polymorphism Analysis 3olverembatinib 2fludarabine 2Watchful Waiting 2Tyrosine Kinase Inhibitors 2Molecular Diagnostic Techniques 2Influenza Vaccines 2Immunologic Techniques 2Immunohistochemistry 2Hydroxyurea 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

5 trials
RecentStart dateEnrollment
Observational × Dasatinib × Myeloid × Clear all
NCT05286528 2023-10-27

Study to Evaluate Chronic Myeloid Leukemia Treatment Landscape and Real-life Treatment Outcomes in Hungary: Analysis of National Health Insurance Fund Database

Pfizer

Completed
1,484 enrolled 6 charts
MyeloidOther hematologic neoplasm

Leukemia, Myelogenous, Chronic, BCR-ABL Positive

NCT03885830 2023-01-11

Precision Dosing of Tyrosine Kinase Inhibitors in CML Patients

UNC Lineberger Comprehensive Cancer Center

Completed
45 enrolled
MyeloidOther hematologic neoplasm

Leukemia, Myelogenous, Chronic, BCR-ABL Positive, Leukemia, Myeloid, Chronic-Phase

NCT02421926 2019-07-08

IDEAL-E

Asan Medical Center

Withdrawn
MyeloidOther hematologic neoplasm

Leukemia, Myelogenous, Chronic, BCR-ABL Positive

NCT02389972 2017-09-11

Effectiveness of Dasatinib in Adult Patients With Chronic Myeloid Leukemia in China: A Multicenter, Registry Study

Bristol-Myers Squibb

Completed
128 enrolled
MyeloidOther hematologic neoplasm

Leukemia, Myelogenous, Chronic, BCR-ABL Positive

NCT02733445 2016-04-11

Metabolic Outcomes in Patients Receiving Tyrosine Kinase Inhibitor (TKI) Therapy With Dasatinib or Nilotinib

Bristol-Myers Squibb

Completed
2,650 enrolled
MyeloidOther hematologic neoplasm

Leukemia, Myelogenous, Chronic, BCR-ABL Positive

Data powered by HemOnc (CC BY 4.0) Colophon âš¡